Patents by Inventor Charles Lester SHEAR

Charles Lester SHEAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240067965
    Abstract: The present disclosure provides pharmaceutic compositions for oral delivery comprising an antisense oligonucleotide (e.g., CIVI 008) and an oral delivery agent such as 5-CNAC. In some aspects, the disclosure provides a capsule comprising a dry blend of CIVI 008 and 5-CNAC, and optionally a statin.
    Type: Application
    Filed: December 10, 2021
    Publication date: February 29, 2024
    Inventors: Henrik OERUM, Stewart Alwyn NOBLE, Charles Lester SHEAR
  • Publication number: 20220380761
    Abstract: The present disclosure provides oligonucleotide compositions comprising (1) an oligonucleotide of the present disclosure, e.g., an ASO, siRNA, shRNA, DNA or RNA aptamer, gene therapy vector, miRNA, miRNA mimic, antimiR, DNA or RNA decoy, CpG oligonucleotide, or any therapeutic or diagnostic oligonucleotide known in the art, and (ii) a caprylic acid derivative, e.g., 5-CNAC. In some aspects, the oligonucleotide composition is formulated for delivery to the gastrointestinal tract. Thus, some aspects, the present disclosure provides oligonucleotide compositions for oral delivery comprising a therapeutic or diagnostic oligonucleotide (e.g., an ASO) and a caprylic acid derivative (e.g., 5-CNAC or de derivative thereof).
    Type: Application
    Filed: April 21, 2022
    Publication date: December 1, 2022
    Applicant: CiVi Biopharma, Inc.
    Inventors: Henrik OERUM, Stewart Alwyn NOBLE, Charles Lester SHEAR
  • Publication number: 20220213476
    Abstract: The present disclosure provides pharmaceutic compositions for oral delivery comprising an antisense oligonucleotide (e.g., CIVI 008) and an oral delivery agent such as 5-CNAC. In some aspects, the disclosure provides a capsule comprising a dry blend of CIVI 008 and 5-CNAC, and optionally a statin.
    Type: Application
    Filed: December 10, 2021
    Publication date: July 7, 2022
    Applicant: CiVi Biopharma, Inc.
    Inventors: Henrik OERUM, Stewart Alwyn NOBLE, Charles Lester SHEAR